Medicus Pharma nine-month net loss widens 32% to USD 35.9 million
MDCX•Medicus Pharma’s net loss for the nine months ended September 30, 2026, widened 32% to USD 35.9 million. Its Q3 net loss narrowed 5% year over year to USD 15.2 million, while operating expenses for the nine-month period rose 30% to USD 34.5 million.
1. Quarterly and nine-month results
Medicus Pharma reported a Q3 2026 net loss of USD 15.2 million, down 5% year over year, and operating expenses of USD 14.5 million, down 6%. For the nine months ended September 30, 2026, its net loss widened 32% to USD 35.9 million and operating expenses rose 30% to USD 34.5 million.
2. Investment and proposed transaction
Management plans to prioritize incremental investment in CD228V and anticipates a substantial reduction in operating expenses in coming quarters. The proposed SkinJect SPAC transaction contemplates a USD 135 million pre-money enterprise valuation, with completion anticipated in the first half of 2027.
